Immunotherapy Approaches for Urothelial Bladder Cancer: Expert Guidance Through Challenging Cases Exploring the Fundamental Changes in Patient Care
  • CME
  • CE

In this virtual presentation, Elizabeth R. Plimack, MD, MS discusses the clinical rationale and data on the use of immune checkpoint inhibitors for patients with advanced bladder cancer. Afterwards, download the slides and use the treatment decision tool for your practice.
Elizabeth R. Plimack, MD, MS
Physicians: maximum of 1.0 AMA PRA Category 1 Credit
Registered Nurses: 1.0 Nursing contact hour
Released: April 30, 2018 Expiration: April 29, 2019

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Differentiate the mechanisms of action and clinical properties of immunotherapy approaches for the treatment of patients with bladder cancer
  • Evaluate the available efficacy and safety data on different immunotherapies and their clinical implications on current therapy decisions in bladder cancer
  • Plan treatment strategies for patients with bladder cancer that include immune checkpoint inhibitors

Information on this Educational Activity

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Faculty

Elizabeth R. Plimack, MD, MS

Chief, Division of Genitourinary Medical Oncology
Director, Genitourinary Clinical Research
Associate Professor, Department of Hematology/Oncology
Fox Chase Cancer Center
Temple Health
Philadelphia, Pennsylvania

Elizabeth R. Plimack, MD, MS, has disclosed that she has received consulting fees from AstraZeneca, Bristol-Myers Squibb, Clovis, Eli Lilly and Company, Exelixis, Genentech, Horizon Pharma, Inovio, Novartis, and Pfizer and funds for research support from Astellas, AstraZeneca, Bristol-Myers Squibb, Genentech, Merck, Peloton, and Pfizer.

Staff

Gordon Kelley

Senior Clinical Editor

Gordon Kelley has no significant financial relationships to disclose.
Tanja Link, PhD

Editorial Contributor

Tanja Link, PhD has no significant financial relationships to disclose.
Krista Marcello

Managing Editor

Krista Marcello has no significant financial relationships to disclose.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD has no significant financial relationships to disclose.
Kristen M. Rosenthal, PhD

Senior Managing Editor

Kristen Rosenthal, PhD has no significant financial relationships to disclose.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

The following PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, RN, BSN and Jan Schultz, RN, MSN, CHCP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for physicians, nurses, and other healthcare professionals who provide care for patients with bladder cancer.

Goal

The goal of this activity is to improve participants’ clinical competence in applying recent practice-changing findings regarding immunotherapies for the treatment of bladder cancer.

Physician Continuing Medical Education


Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Clinical Care Options, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation

The Postgraduate Institute for Medicine designates this online activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from April 30, 2018, through April 29, 2019:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME activities completed can be found on the "CME Manager" page. There are no costs/fees for this activity.

Related Content

Analysis of phase III IMpower132 trial evaluating the addition of atezolizumab to first-line chemotherapy in NSCLC: PFS, safety, and interim OS.

Released: September 28, 2018

Results from phase I/III IMpower133 trial evaluating addition of atezolizumab to first-line chemotherapy in extensive-stage SCLC from WCLC 2018 reported by Clinical Care Options (CCO).

Released: September 28, 2018

Results from PACIFIC trial of durvalumab after chemoradiotherapy (CRT) in unresectable stage III NSCLC from WCLC 2018 reported by Clinical Care Options (CCO).

Released: September 28, 2018

Interim analysis of the phase III ALTA-1L trial of brigatinib vs crizotinib in ALK inhibitor–naive patients with ALK-positive advanced NSCLC

Released: September 27, 2018
Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC.
PIM Logo

Postgraduate Institute for Medicine
304 Inverness Way South, Suite 100
Englewood, CO 80112

Allison Hughes, CCMEP, Program Manager
(303) 799-1930
(303) 858-8842 (Fax)
ahughes@pimed.com
www.pimed.com

This activity is supported by an educational grant from
Merck & Co., Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?